Compounded semaglutide — what U.S. buyers need to know in 2026

Compounded semaglutide in 2026: how it differs from branded GLP-1s, what compounders changed after FDA enforcement, dosing presentations, and how to vet…

Compounded semaglutide is a non-FDA-approved preparation of the semaglutide molecule made by a licensed U.S. compounding partner. In 2026 the responsible suppliers ship with third-party COAs, signed buyer agreements, and clearly labeled research / investigational / licensed-professional use only.

Semaglutide is the GLP-1 receptor agonist behind several of the most prescribed weight and metabolic drugs in the United States. Compounded semaglutide is the same molecule prepared by a licensed U.S. compounding partner. The category exploded in 2023–2024, contracted under FDA enforcement in 2024–2025, and is now in a more mature, supply-stable phase in 2026.

How compounded differs from branded semaglutide

Branded semaglutide products (Ozempic®, Wegovy®, Rybelsus®) are FDA-approved drugs manufactured under their sponsor's specifications. Compounded semaglutide is prepared by a licensed compounding pharmacy or compounding partner to a specified concentration and presentation; it is not FDA-approved and is not bioequivalent or interchangeable with the branded products from a regulatory standpoint.

What buyers actually care about — molecule, concentration, sterility, batch documentation — comes from the compounder's QA process, not from the FDA approval status. That's why supplier diligence matters far more in the compounded lane.

What changed under FDA enforcement

• The FDA's removal of semaglutide from the formal drug-shortage list in early 2025 narrowed the compounding lane.
• Reputable U.S. compounders tightened to research-use, investigational-use, and licensed-professional-use frameworks.
• Bulk telehealth operations that blurred the line have largely consolidated, exited, or rebuilt under stricter protocols.
• Buyers should now expect a written purchase agreement and clear labeling — not just a checkout flow.

Common compounded semaglutide presentations

• 2 mg / vial — common starter presentation, lower dose titration.
• 5 mg / vial — mainstream maintenance presentation.
• 10 mg / vial — extended-protocol or research presentation.
• Reconstitution with bacteriostatic water; reconstituted vials are typically refrigerated and used within ~28 days.

Vetting a compounded semaglutide supplier in 2026

• Third-party COA per batch with peptide content and purity.
• Named U.S. compounding partner and verifiable address.
• Clear research / investigational / licensed-professional-use labeling.
• Signed Peptide Agreement before first order.
• Cold-chain shipping policy with stated stability window after reconstitution.

Related peptides

• Semaglutide — A long-acting GLP-1 receptor agonist extensively studied for metabolic health.
• Tirzepatide — Dual GIP and GLP-1 receptor agonist studied for metabolic and weight outcomes.
• Retatrutide — Triple-receptor (GLP-1 / GIP / glucagon) agonist in late-stage clinical trials.

Sources

• FDA: Medications containing semaglutide marketed for type 2 diabetes or weight loss — U.S. Food & Drug Administration (accessed 2026-06-27): https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
• FDA Drug Shortages: Semaglutide injection — resolved status — U.S. Food & Drug Administration (accessed 2026-06-27): https://www.accessdata.fda.gov/scripts/drugshortages/
• Once-weekly semaglutide in adults with overweight or obesity (STEP 1) — New England Journal of Medicine (accessed 2026-06-27): https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• USP <797> Pharmaceutical Compounding — Sterile Preparations — United States Pharmacopeia (accessed 2026-06-27): https://www.usp.org/compounding/general-chapter-797

Important

All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.

Frequently asked questions

Is compounded semaglutide the same as Ozempic or Wegovy?

No. Compounded semaglutide contains the semaglutide molecule but is not the same FDA-approved product as Ozempic or Wegovy and is not regulated as such.

Is compounded semaglutide legal in the U.S.?

Compounded semaglutide can be legally prepared by a licensed U.S. compounding partner for research, investigational, or licensed professional use, subject to FDA and state pharmacy regulations.

What concentration does Clarity Wellness offer?

We rotate 2 mg, 5 mg, and 10 mg vial presentations based on supply. Members see current concentrations and pricing in the catalog after signing in with a VIP code.

How do I store compounded semaglutide?

Lyophilized vials are kept refrigerated. After reconstitution with bacteriostatic water, most preparations are kept at 2–8°C and used within roughly 28 days. Always defer to the specific compounder's labeled stability window.

Do I need a prescription?

Clarity Wellness sells compounded peptides on a research / investigational / licensed-professional-use basis under a signed Peptide Agreement. We are not a pharmacy and do not dispense prescriptions.